Much to the delight, recent disclosures perspicuously underscore the favourable trends witnessed with PARP inhibitors in endometrial cancer such as: (i) the promising efficacy of olaparib in advanced endometrial carcinoma31 (ii) pathologic complete response of high-grade endometrial cancer to PARP inhibitors32 (iii) optimistic activity profile of a triplet regimen consisting of PARP inhibitor in recurrent, advanced endometrial carcinoma33 (iv) manifestation of efficacy by olaparib, in cultured endometrial carcinoma cells.34 This evidence concerns the gene PARP1 and endometrial cancer.